Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

58 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase 2 study of ibrutinib in classic and variant hairy cell leukemia.
Rogers KA, Andritsos LA, Wei L, McLaughlin EM, Ruppert AS, Anghelina M, Blachly JS, Call T, Chihara D, Dauki A, Guo L, Ivy SP, James LR, Jones D, Kreitman RJ, Lozanski G, Lucas DM, Ngankeu A, Phelps M, Ravandi F, Schiffer CA, Carson WE, Jones JA, Grever MR. Rogers KA, et al. Among authors: mclaughlin em. Blood. 2021 Jun 24;137(25):3473-3483. doi: 10.1182/blood.2020009688. Blood. 2021. PMID: 33754642 Free PMC article. Clinical Trial.
Incidence, Treatment, and Survival of Patients With T-Cell Lymphoma, T-Cell Large Granular Leukemia, and Concomitant Plasma Cell Dyscrasias.
Braunstein Z, McLaughlin E, Ruiz M, Wei L, Bumma N, Benson D, Devarakonda S, Chaudhry M, Khan A, Cottini F, Hanel W, Baiocchi R, Chung C, Addison D, Couette N, Meara A, Jarjour W, Porcu P, Mishra A, Reneau JC, Rosko AE, Brammer JE. Braunstein Z, et al. Front Oncol. 2022 Apr 29;12:858426. doi: 10.3389/fonc.2022.858426. eCollection 2022. Front Oncol. 2022. PMID: 35574379 Free PMC article.
A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma.
Hanel W, Shindiapina P, Bond DA, Sawalha Y, Epperla N, Voorhees T, Welkie RL, Huang Y, Behbehani GK, Zhang X, McLaughlin E, Chan WK, Brammer JE, Jaglowski S, Reneau JC, Christian BA, William BM, Cohen JB, Baiocchi RA, Maddocks K, Blum KA, Alinari L. Hanel W, et al. Cancers (Basel). 2023 Feb 24;15(5):1437. doi: 10.3390/cancers15051437. Cancers (Basel). 2023. PMID: 36900230 Free PMC article.
Glassy cell carcinoma of the cervix: Findings from a combined National Cancer Database analysis and single institution review of treatment patterns and outcomes.
Levine MD, Barrington DA, Meade CE, Lammers SM, McLaughlin EM, Suarez AA, Backes FJ, Copeland LJ, O'Malley DM, Cosgrove CM, Cohn DE, Nagel CI, Felix AS, Bixel KL. Levine MD, et al. Among authors: mclaughlin em. Gynecol Oncol. 2023 Jun;173:15-21. doi: 10.1016/j.ygyno.2023.03.023. Epub 2023 Apr 8. Gynecol Oncol. 2023. PMID: 37037083
Recurrence rate in early-stage epithelial ovarian cancer: Is there a role for upfront maintenance with PARP inhibitors in stages I and II?
Levine MD, O'Malley DM, Haight PJ, Senter L, Wagner V, Bixel KL, Cohn DE, Copeland LJ, Cosgrove CM, McLaughlin EM, Backes FJ. Levine MD, et al. Among authors: mclaughlin em. Gynecol Oncol Rep. 2023 Mar 31;46:101173. doi: 10.1016/j.gore.2023.101173. eCollection 2023 Apr. Gynecol Oncol Rep. 2023. PMID: 37082521 Free PMC article.
Assessment of the feasibility of same-day discharge following minimally invasive hysterectomy in the elderly population.
Haight PJ, Piver RN, Barrington DA, Baek J, Graves SM, Ardizzone M, Akinduro JA, Busho AC, Fadoju D, Pandit R, Stephens R, Strowder LM, Tadepalli S, VanNoy B, Sriram B, McLaughlin EM, Ds Lightfoot M, Chambers LM, Bixel KL, Cohn DE, Cosgrove CM, O'Malley D, Salani R, Backes FJ, I Nagel C. Haight PJ, et al. Among authors: mclaughlin em. Gynecol Oncol Rep. 2023 Jun 19;48:101227. doi: 10.1016/j.gore.2023.101227. eCollection 2023 Aug. Gynecol Oncol Rep. 2023. PMID: 37415961 Free PMC article.
58 results